JP2019519770A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519770A5
JP2019519770A5 JP2018562324A JP2018562324A JP2019519770A5 JP 2019519770 A5 JP2019519770 A5 JP 2019519770A5 JP 2018562324 A JP2018562324 A JP 2018562324A JP 2018562324 A JP2018562324 A JP 2018562324A JP 2019519770 A5 JP2019519770 A5 JP 2019519770A5
Authority
JP
Japan
Prior art keywords
cells
biomarker
sequence
peripheral
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018562324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519770A (ja
JP7066639B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/063045 external-priority patent/WO2017207574A1/en
Publication of JP2019519770A publication Critical patent/JP2019519770A/ja
Publication of JP2019519770A5 publication Critical patent/JP2019519770A5/ja
Priority to JP2022072884A priority Critical patent/JP7511806B2/ja
Application granted granted Critical
Publication of JP7066639B2 publication Critical patent/JP7066639B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018562324A 2016-05-30 2017-05-30 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 Active JP7066639B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022072884A JP7511806B2 (ja) 2016-05-30 2022-04-27 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16171885 2016-05-30
EP16171885.3 2016-05-30
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022072884A Division JP7511806B2 (ja) 2016-05-30 2022-04-27 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法

Publications (3)

Publication Number Publication Date
JP2019519770A JP2019519770A (ja) 2019-07-11
JP2019519770A5 true JP2019519770A5 (https=) 2020-07-16
JP7066639B2 JP7066639B2 (ja) 2022-05-13

Family

ID=56116221

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018562324A Active JP7066639B2 (ja) 2016-05-30 2017-05-30 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法
JP2022072884A Active JP7511806B2 (ja) 2016-05-30 2022-04-27 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022072884A Active JP7511806B2 (ja) 2016-05-30 2022-04-27 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法

Country Status (26)

Country Link
US (2) US20190195879A1 (https=)
EP (2) EP3916392B1 (https=)
JP (2) JP7066639B2 (https=)
KR (1) KR102416144B1 (https=)
CN (2) CN115932265B (https=)
AU (1) AU2017272608B2 (https=)
CY (1) CY1124768T1 (https=)
DK (2) DK3916392T3 (https=)
EA (1) EA201892542A1 (https=)
ES (2) ES2981046T3 (https=)
FI (1) FI3916392T3 (https=)
HR (2) HRP20240670T1 (https=)
HU (2) HUE067450T2 (https=)
IL (1) IL263103B2 (https=)
LT (2) LT3916392T (https=)
MA (2) MA57021B1 (https=)
MD (2) MD3465214T2 (https=)
MX (2) MX388502B (https=)
PL (2) PL3916392T3 (https=)
PT (2) PT3916392T (https=)
RS (2) RS62155B1 (https=)
SG (2) SG10201911958SA (https=)
SI (2) SI3916392T1 (https=)
SM (2) SMT202400204T1 (https=)
WO (1) WO2017207574A1 (https=)
ZA (2) ZA201808647B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100541T1 (it) 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
IL301786B2 (en) 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2021013101A (es) * 2019-05-03 2022-01-04 Morphosys Ag Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
EP4051317A1 (en) * 2019-10-31 2022-09-07 MorphoSys AG Sequential anti-cd19 therapy
TWI865644B (zh) * 2019-10-31 2024-12-11 德商莫菲西斯公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
US20230014026A1 (en) * 2020-06-22 2023-01-19 Morphosys Ag Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
US20220184208A1 (en) * 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
WO2026024668A1 (en) * 2024-07-22 2026-01-29 Abbott Laboratories Method of determining a volume of a liquid in a sample

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
AU2002306596B2 (en) 2001-02-27 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
KR101335798B1 (ko) * 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
US20100167315A1 (en) 2006-09-13 2010-07-01 Glycode Method for investigating the response to a treatment with a monoclonal antibody
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
AU2011329161A1 (en) 2010-11-15 2013-06-27 Medimmune, Llc Combination therapy for B cell lymphomas
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PL2744515T3 (pl) 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
HUE058855T2 (hu) * 2011-08-16 2022-09-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
EP2791165A4 (en) * 2011-12-12 2015-08-05 Pikamab Inc PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY
US9139649B2 (en) * 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
JP2017519757A (ja) 2014-06-16 2017-07-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． 慢性リンパ球性白血病（ｃｌｌ）の処置
US10969391B2 (en) 2014-07-11 2021-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers

Similar Documents

Publication Publication Date Title
JP2019519770A5 (https=)
FI3916392T3 (fi) Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla
RU2017143166A (ru) Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение
Roufosse et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome
JP2022002520A5 (https=)
JP2022119854A5 (https=)
JP2013542194A5 (https=)
Intongkam et al. Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and/or biologics therapy
JP2021523213A5 (https=)
FI3110440T3 (fi) Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi
RU2014103490A (ru) Комбинированная терапия с помощью антитела к cd19 и аналога пурина
RU2019113370A (ru) Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения
FI3699198T3 (fi) Menetelmiä kasvaimen hoitoon bispesifistä CD3XCD20-vasta-ainetta käyttämällä
JP2017507954A5 (https=)
JP2021500916A5 (https=)
IL310079A (en) TIM-3 antagonists for the treatment and diagnosis of cancer
RU2018107929A (ru) Комбинации и их использование
HRP20210945T1 (hr) Formulacije protutijela anti-cd19
JP2012519707A5 (https=)
RU2014103492A (ru) Комбинированная терапия антителом к cd19 и азотистым ипритом
JP2017503481A5 (https=)
van Hooij et al. BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease
JP2020500161A5 (https=)
JP2020523384A5 (https=)
Gärtner et al. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery